Mersana Therapeutics (NASDAQ: MRSN) reported Q2 EPS of ($4.87), $4.71 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $3.06 million versus the consensus estimate of $6.25 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.